Announcements Trials
Browse Landscape

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 11Observational 3

Sponsor

Cancer Type

Breast 5Tumor-Agnostic 3CNS 2

Conditions

Neoplasms 3

Interventions

Surveys and Questionnaires 48Blood Specimen Collection 22Interviews as Topic 14Data Collection 11Magnetic Resonance Spectroscopy 6Hematologic Tests 6Specimen Handling 5Restraint, Physical 5Radiotherapy 5Palliative Care 4Observation 4Mental Status and Dementia Tests 4Watchful Waiting 3Registries 3Quality of Life 3Phlebotomy 3Neoadjuvant Therapy 3Magnetic Resonance Imaging 3Lapatinib 3Immunotherapy 3Immune Checkpoint Inhibitors 3Health Records, Personal 3Focus Groups 3Drug Therapy 3Bevacizumab 3Absorptiometry, Photon 3veliparib 2talazoparib 2rucaparib 2pamiparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Observational × Lapatinib × Tumor-Agnostic × Clear all
NCT05467189 2022-07-20

Antineoplastic Drugs in Elderly Patients

Shandong University

Recruiting
500 enrolled
Tumor-Agnostic

Neoplasms

NCT01332396 2017-04-26

Drug Use Investigation for TYKERB Tablet (All Case Investigation)

Novartis

Completed
4,054 enrolled
Tumor-Agnostic

Neoplasms

NCT00975988 2014-10-27

Regulatory TYKERB® Tablets PMS

GlaxoSmithKline

Completed
750 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡